Results 241 to 250 of about 86,585 (334)

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report [PDF]

open access: yes, 2019
Callebout, Eduard   +7 more
core   +2 more sources

Emerging Biosensor Technologies for Stroke Biomarker Detection: A Comprehensive Overview

open access: yesAnalytical Science Advances, Volume 6, Issue 2, December 2025.
ABSTRACT Stroke remains a leading cause of morbidity and mortality worldwide, necessitating the development of rapid and reliable diagnostic tools for early detection and management. This manuscript presents an overview of innovative biosensors designed for the detection of key stroke biomarkers, including N‐terminal pro B‐type natriuretic peptide (NT ...
Ghazal Koohkansaadi   +3 more
wiley   +1 more source

A primary lung carcinoma producing alpha-fetoprotein, carcinoembryonic antigen, and human chorionic gonadotropin. Immunohistochemical and biochemical studies [PDF]

open access: bronze, 1987
Tomohiro Yoshimoto   +8 more
openalex   +1 more source

Beyond the tumor: Enhancing pancreatic cancer therapy through glutamine metabolism and innovative drug delivery

open access: yesJournal of Cell Communication and Signaling, Volume 19, Issue 3, September 2025.
The top row shows key drivers‐KRAS, c‐Myc and HIF‐1a‐alongside gut and tumor microbiota, all converging on glutamine metabolism in PDAC. At the center, glutamine handling is depicted as the linchpin of tumor growth, biosynthesis and immune modulation. The green panel lists major intervention strategies: DON‐loaded nanoparticles, prodrugs (DRP‐104/JHU ...
Min Su   +4 more
wiley   +1 more source

Influence of age and sex on the diagnostic accuracy of pleural fluid carcinoembryonic antigen for malignant pleural effusion: a <i>post hoc</i> analysis. [PDF]

open access: yesFront Oncol
Yang DN   +14 more
europepmc   +1 more source

Carcinoembryonic antigen in primary carcinoid tumors of the lung [PDF]

open access: bronze, 1986
George A. Bishopric, Nelson G. Ordóǹez
openalex   +1 more source

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

open access: yesMedComm – Oncology, Volume 4, Issue 3, September 2025.
Immune checkpoints in tumor immunotherapy. Ligand binding to the receptor inhibits immune cell function, promotes tumor cell immune escape, and suppresses the immune response. The pathways of action are VISTA‐IGSF11, TIM‐3‐Ceacam1, CD47‐SIRPα, CTLA‐4‐CD80/CD86, PD‐L1‐PD‐1, MHC‐1‐LILRB, and CD24 ‐ Siglec ‐10. There are also other immune checkpoints such
Han Sun   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy